Rigel Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $195.29 million
- Book Value:
- Revenue TTM:
- $121.14 million
- Operating Margin TTM:
- Gross Profit TTM:
- $53.72 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Rigel Pharmaceuticals Inc had its IPO on 2000-11-29 under the ticker symbol RIGL.
The company operates in the Healthcare sector and Biotechnology industry. Rigel Pharmaceuticals Inc has a staff strength of 155 employees.
Shares of Rigel Pharmaceuticals Inc opened at $1.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.08 - $1.12, and closed at $1.08.
This is a -3.57% slip from the previous day's closing price.
A total volume of 382,565 shares were traded at the close of the day’s session.
In the last one week, shares of Rigel Pharmaceuticals Inc have slipped by -8.47%.
Rigel Pharmaceuticals Inc's Key Ratios
Rigel Pharmaceuticals Inc has a market cap of $195.29 million, indicating a price to book ratio of 31.6366 and a price to sales ratio of 2.5561.
In the last 12-months Rigel Pharmaceuticals Inc’s revenue was $121.14 million with a gross profit of $53.72 million and an EBITDA of $-36619000. The EBITDA ratio measures Rigel Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Rigel Pharmaceuticals Inc’s operating margin was -31.2% while its return on assets stood at -19.28% with a return of equity of -699.05%.
In Q2, Rigel Pharmaceuticals Inc’s quarterly earnings growth was a positive 74.5% while revenue growth was a negative 13.2%.
Rigel Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rigel Pharmaceuticals Inc’s profitability.
Rigel Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.6925 and a EV to EBITDA ratio of -1.9478. Its price to sales ratio in the trailing 12-months stood at 2.5561.
Rigel Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $117.09 million
- Total Liabilities
- $44.02 million
- Operating Cash Flow
- $2.97 million
- Capital Expenditure
- Dividend Payout Ratio
Rigel Pharmaceuticals Inc ended 2023 with $117.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $117.09 million while shareholder equity stood at $-28115000.00.
Rigel Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $44.02 million in other current liabilities, 175000.00 in common stock, $-1402595000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.81 million and cash and short-term investments were $64.36 million. The company’s total short-term debt was $466,000 while long-term debt stood at $59.57 million.
Rigel Pharmaceuticals Inc’s total current assets stands at $100.93 million while long-term investments were $0 and short-term investments were $15.55 million. Its net receivables were $20.82 million compared to accounts payable of $5.24 million and inventory worth $10.78 million.
In 2023, Rigel Pharmaceuticals Inc's operating cash flow was $2.97 million while its capital expenditure stood at $0.
Comparatively, Rigel Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Rigel Pharmaceuticals Inc stock is currently trading at $1.08 per share. It touched a 52-week high of $2.04 and a 52-week low of $2.04. Analysts tracking the stock have a 12-month average target price of $4.17.
Its 50-day moving average was $1.23 and 200-day moving average was $1.35 The short ratio stood at 3.13 indicating a short percent outstanding of 0%.
Around 143.6% of the company’s stock are held by insiders while 6591.5% are held by institutions.
Frequently Asked Questions About Rigel Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company’s other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.